SARS-CoV-2 seroprevalence
| First study visit (November 2020) | Second study visit (December 2020) | |
| Seroprevalence % (CI) | 1.7 (0.3 to 3.3) | 6.8 (3.8 to 10.1) |
| Seroprevalence % (CI)—for participants with two samples available | 5.5 (2.3 to 8.7) | |
| Number of participants who reported cold-like symptoms between study visits | 92 | |
| Seroprevalence % (CI)—for participants with cold-like symptoms | 7.6 (3.3 to 13.0) | |
| Seroprevalence % (CI)—for participants without cold-like symptoms | 6.2 (2.8 to 10.3) | |
| Ratio of undetected to detected cases | 1/4 (0.25) | 4/12 (0.33) |
| Ratio of undetected to detected cases in participants with mandated quarantine measures between visits | 1/4 (0.25) |